Division of Vascular and Endovascular Surgery, Department of Surgery, University of California San Diego, La Jolla, California; Division of Vascular and Endovascular Surgery, Department of Surgery, University at Buffalo, Buffalo, New York.
Division of Vascular and Endovascular Surgery, Department of Surgery, University of California San Diego, La Jolla, California.
J Surg Res. 2023 Nov;291:670-676. doi: 10.1016/j.jss.2023.06.021. Epub 2023 Aug 8.
Prior studies have demonstrated acceptable midterm outcomes with prosthetic conduits for above-knee bypass for occlusive disease in patients with inadequate segment great saphenous vein (GSV). In this study we aimed to investigate whether this holds true for open repair of popliteal artery aneurysms (PAA).
We queried the Vascular Quality Initiative data for patients who underwent open PAA repair (OPAR). We divided the cohort into three groups based on the conduit used: GSV, other autologous veins, or prosthetic graft. Study outcomes included primary patency, freedom from major amputation, amputation-free survival, and overall survival at 1 y. Kaplan-Meier survival estimates, log-rank tests and multivariable Cox regression were used to compare outcomes between study groups.
A total of 4016 patients underwent bypass for PAA from January 2010 to October 2021. The three cohorts were significantly different in many demographic and clinical characteristics. The adjusted odds of postoperative amputation among symptomatic patients were 3-fold higher for prosthetic conduits compared to the GSV (odds ratio, 3.20; 95% CI, 1.72-5.92; P < 0.001). For the 1-y outcomes, the adjusted risk of major amputation was almost 3-fold higher for patients with symptomatic disease undergoing bypass with prosthetic conduits (hazard ratio [HR], 2.97; 95% CI, 1.35-6.52; P = 0.007). When compared with GSV, prosthetic conduits were associated with 96% increased risk of death when used for repair in symptomatic patients (adjusted hazard ratio (aHR), 1.96; 95% CI, 1.29-2.97; P = 0.002) but no significant association with mortality in asymptomatic patients (aHR, 0.83; 95% CI, 0.37-1.87; P = 0.652). When compared with GSV, prosthetic conduits were associated with a 2-fold increased risk of 1-y major amputation or death when used for repair in symptomatic patients (aHR, 2.03; 95% CI, 1.40-2.94; P < 0.001) but no significant association with mortality in asymptomatic patients (aHR, 0.91; 95% CI, 0.42-1.98; P = 0.816). Comparing bypass with other veins to the GSV among patients with symptomatic disease, there was no statistically significant difference in major amputation risk (HR; 2.44; 95% CI, 0.55-10.82; P = 0.242) and no difference in the adjusted risk of all-cause mortality (aHR, 0.77; 95% CI, 0.26-2.44; P = 0.653). There were no differences in the adjusted risk of loss of primary patency comparing other veins to GSV (HR, 1.53; 95% CI, 0.85-2.76; P = 0.154) and prosthetic conduits to GSV (HR, 0.85; 95% CI, 0.57-1.26; P = 0.422).
This large study shows that among patients undergoing OPAR, 1-y primary patency does not differ between conduit types. However, prosthetic conduits are associated with significantly higher risk of amputation and death compared to GSV among symptomatic patients. Though non-GSV autologous veins are less often used for OPAR, they have comparably acceptable outcomes as GSV.
先前的研究表明,对于伴有大隐静脉(GSV)不足的闭塞性疾病的膝上旁路,使用假体血管进行旁路手术具有可接受的中期结果。在这项研究中,我们旨在探讨对于腘动脉瘤(PAA)的开放修复是否也是如此。
我们查询了血管质量倡议(Vascular Quality Initiative)的数据,以确定接受 PAA 开放修复(OPAR)的患者。我们根据使用的血管分为三组:GSV、其他自体静脉或假体移植物。研究结果包括 1 年时的主要通畅率、免于主要截肢、无截肢生存率和总体生存率。Kaplan-Meier 生存估计、对数秩检验和多变量 Cox 回归用于比较研究组之间的结果。
2010 年 1 月至 2021 年 10 月,共有 4016 例患者接受了 PAA 的旁路手术。在许多人口统计学和临床特征方面,这三个队列存在显著差异。对于有症状的患者,与 GSV 相比,假体移植物术后截肢的调整后优势比为 3 倍(比值比,3.20;95%置信区间,1.72-5.92;P<0.001)。对于 1 年的结果,与 GSV 相比,在有症状的疾病患者中使用假体移植物进行旁路手术时,主要截肢的调整风险几乎高出 3 倍(风险比[HR],2.97;95%置信区间,1.35-6.52;P=0.007)。与 GSV 相比,在有症状的患者中,假体移植物与死亡风险增加 96%相关(调整后的危险比[aHR],1.96;95%置信区间,1.29-2.97;P=0.002),但在无症状患者中与死亡率无显著关联(aHR,0.83;95%置信区间,0.37-1.87;P=0.652)。与 GSV 相比,在有症状的患者中,使用假体移植物进行旁路手术时,1 年时主要截肢或死亡的调整后风险增加 2 倍(aHR,2.03;95%置信区间,1.40-2.94;P<0.001),但在无症状患者中与死亡率无显著关联(aHR,0.91;95%置信区间,0.42-1.98;P=0.816)。对于有症状的患者,与 GSV 相比,比较使用其他静脉旁路与 GSV 旁路,主要截肢风险没有统计学差异(HR,2.44;95%置信区间,0.55-10.82;P=0.242),全因死亡率的调整风险也没有差异(aHR,0.77;95%置信区间,0.26-2.44;P=0.653)。与 GSV 相比,比较其他静脉与 GSV 时,主要通畅率的调整风险没有差异(HR,1.53;95%置信区间,0.85-2.76;P=0.154),假体移植物与 GSV 相比,主要通畅率的调整风险也没有差异(HR,0.85;95%置信区间,0.57-1.26;P=0.422)。
这项大型研究表明,在接受 OPAR 的患者中,不同血管类型之间 1 年的主要通畅率没有差异。然而,与 GSV 相比,假体移植物在有症状的患者中与更高的截肢和死亡风险相关。虽然非 GSV 自体静脉在 OPAR 中较少使用,但它们的结果与 GSV 相当。